Track topics on Twitter Track topics that are important to you
AstraZeneca has entered into a global collaboration with US drugmaker Merck to develop and commercialize the former’s investigational cancer treatments Lynparza (olaparib) and selumetinib. Lynparza is a first-in-class oral poly ADP ribose polymerase (PARP) inhibitor that is approved for BRCA-mutated ovarian cancer in multiple lines of treatment. The therapy has 14 indications currently being developed across several tumor types, including breast, prostate and pancreatic tumors.
Original Article: AstraZeneca and Merck in Global Oncology PactNEXT ARTICLE
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...
Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...
Merck and Co
Merck & Co is the 7th largest pharmaceutical company in the world based on annual sales, which reached $25,236m in 2009. They have developed 14 vaccines and over 40 prescription products in the major therapeutic areas of cardiovascular disease, respi...